leadf
logo-loader
viewRexahn Pharmaceuticals, Inc.

Rexahn Pharmaceuticals stock sinks after announcing direct share offering

The offering is expected to generate gross proceeds of $5.7 million

research on cancer
Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company.

Shares of Rexahn Pharmaceuticals Inc (AMEX:RNN) sank on Wednesday after the company announced a $7.5 million registered direct offering.

The company said it has entered into an agreement with institutional investors to purchase approximately 5.77 million shares of its common stock and warrants exercisable for up to approximately 5.77 million shares of its common stock to generate gross proceeds of approximately $7.5 million.

The shares and warrants are being sold in units, each consisting of one share of common stock and a warrant to purchase one share of common stock, at an offering price of $1.30 per unit, a 22% discount from the Tuesday closing price of Rexahn.

Shares of Rexahn were trading 28.275 down at $1.20, having touched a session and 52-week low of $1.16.

READ: Rexahn Pharmaceuticals' RX-3117 could be a blockbuster, says HC Wainwright

The warrants will be exercisable six months following the date of issuance and will expire on the fifth anniversary of the initial exercise date and will have an exercise price of $1.67 per share, which was the closing price on Tuesday. The closing of the offering is expected to take place on or about October 19, 2018.

The net proceeds of the offering will be used for further development of Rexahn’s lead clinical programs, including the funding of clinical development programs for RX-3117 and RX-5902, which are supposed to fight cancer. The funds will also be used for working capital and general corporate purposes.

Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to developing novel, targeted therapeutics for the treatment of cancer.

The company is based in Rockville, Maryland.

Reporting by Rene Pastor, contactable on [email protected]

Quick facts: Rexahn Pharmaceuticals, Inc.

Price: - -

AMEX:RNN
Market: AMEX
Market Cap: -
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

CO2 GRO sees 20% higher pepper yields though 10 weeks of Hidroexpo Feasibility

CO2 GRO (CVE: GROW- OTCQB: BLONF) Vice President of Sales and Strategic Alliances Aaron Archibald joined Steve Darling from Proactive to bring details the company has seen very good results from their CO2 Delivery Solution commercial feasibility on greenhouse-grown peppers with Hidroexpo in...

2 days, 4 hours ago

2 min read